Morepen Laboratories

65.36
+1.42
(2.22%)
Market Cap
3,581.40 Cr
EPS
2.20
PE Ratio
30.34
Dividend Yield
0.31 %
Industry
Healthcare
52 Week High
100.90
52 Week Low
42.00
PB Ratio
3.09
Debt to Equity
0.03
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
neutral
Morepen Laboratories has decreased its ownership stake in Morepen Medipath Ltd to 60% following a new share issuance. The news suggests a dilution of Morepen Laboratories' ownership in its subsidiary due to additional shares being issued.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,676.30
#1 4,02,200.50
35.07
#1 52,041.20
12.06
#1 10,980
-18.99
48.33
6,906.50
1,83,345.90
83.65
9,360.00
0.89
2,117
23.05
68.54
1,513.30
1,22,230.40
23.76
28,409.50
7.12
5,291
30.28
54.26
3,368.00
1,13,988.40
59.12
11,317.00
11.59
2,054
10.91
62.08
1,307.40
1,09,111.80
#1 19.63
33,741.20
12.36
5,725
21.14
54.13
1,001.00
1,00,724.00
21.57
22,573.80
13.82
3,977
-0.19
69.99
2,439.50
1,00,685.20
50.68
12,207.40
19.57
1,925
-10.91
59.65
1,980.90
90,466.80
27.51
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,735.00
73,809.50
52.20
6,409.15
10.80
1,417
27.83
64.97
1,191.30
69,190.90
20.01
31,378.10
17.55
3,366
-0.50
63.70
Forecast
Actual
Growth Rate
Revenue Growth
19.72 %
Net Income Growth
149.61 %
Cash Flow Change
180.48 %
ROE
121.79 %
ROCE
113.54 %
EBITDA Margin (Avg.)
68.27 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
489
524
538
586
615
664
858
1,070
1,111
1,293
1,778
Fixed Assets
323
297
272
264
236
216
225
252
267
307
442
Current Assets
115
157
192
243
300
372
527
734
756
889
1,159
Capital Work in Progress
0
0
0
0
0
0
2
14
17
25
28
Investments
0
0
0
0
0
1
1
0
0
1
300
Other Assets
167
227
267
321
379
446
631
804
827
960
0
Total Liabilities
489
524
538
586
615
664
858
1,070
1,111
1,293
1,778
Current Liabilities
128
167
325
340
339
351
404
457
321
402
501
Non Current Liabilities
74
58
18
20
23
28
30
36
37
44
91
Total Equity
287
300
196
226
253
284
424
578
752
847
1,156
Reserve & Surplus
78
91
106
136
163
194
291
457
651
745
1,047
Share Capital
210
210
90
90
90
90
90
96
102
102
110

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-0
-5
3
-1
4
4
28
-26
6
-5
Investing Activities
-32
-27
-14
-27
-13
-13
-70
-32
-47
-83
Operating Activities
51
50
41
63
17
11
51
-60
-91
73
Financing Activities
-19
-27
-24
-38
-0
6
47
66
144
5

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
May 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Aug 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
34.54 %
34.54 %
34.54 %
34.54 %
38.38 %
36.74 %
36.74 %
38.22 %
38.22 %
38.22 %
38.22 %
38.22 %
38.22 %
38.22 %
38.22 %
35.65 %
35.65 %
35.65 %
35.65 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.29 %
0.00 %
1.85 %
1.67 %
7.72 %
2.08 %
2.22 %
1.94 %
DIIs
2.89 %
2.03 %
1.26 %
1.16 %
1.07 %
4.07 %
4.07 %
3.60 %
3.74 %
2.93 %
2.33 %
2.28 %
2.00 %
2.15 %
2.15 %
2.90 %
1.70 %
1.64 %
1.67 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
42.97 %
43.89 %
44.82 %
45.18 %
42.50 %
40.88 %
40.91 %
43.63 %
44.03 %
45.04 %
45.49 %
45.56 %
44.44 %
45.03 %
45.22 %
41.89 %
48.16 %
48.35 %
48.76 %
Others
19.60 %
19.54 %
19.38 %
19.12 %
18.05 %
18.31 %
18.29 %
14.53 %
13.99 %
13.80 %
13.95 %
12.64 %
15.33 %
12.74 %
12.74 %
11.83 %
12.41 %
12.12 %
11.96 %
No of Share Holders
1,65,609
2,30,611
2,44,924
2,55,155
2,60,933
2,83,547
2,87,115
2,87,370
3,06,030
3,06,150
3,01,832
3,04,001
3,04,289
3,36,019
3,48,766
3,52,839
4,30,929
4,48,361
4,68,860

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
12 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 May 2025 61.03 60.36
10 Feb 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
10 Feb 2025 67.45 58.53
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 62.01 62.68
11 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2024 85.93 80.26
28 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Sept 2024 94.70 86.63
18 Mar 2024 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
18 Mar 2024 53.30 42.10
02 Feb 2023 CHANGE OF NAME Change Of Name
NA
02 Feb 2023 27.85 27.85

Announcements

Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 20156 days ago
Closure of Trading Window9 days ago
Announcement under Regulation 30 (LODR)-Change in ManagementJun 21, 2025
Incorporation Of A Wholly Owned Subsidiary In Dubai United Arab Emirates.Jun 18, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 04, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMay 23, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)May 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
Results - Q4 & FY 25May 12, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 12, 2025
Appointment Of Cost Auditors And Internal Auditors Of The CompanyMay 12, 2025
Intimation Of Formation Of A Step Down Subsidiary Company In Dubai UAEMay 12, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMay 12, 2025
Corporate Action-Board approves DividendMay 12, 2025
Audited Financial Results (Consolidated And Standalone) For The Quarter / Year Ended March 31 2025May 12, 2025
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of DirectorsMay 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
Board Meeting Intimation for Financial Results Q4 & FY25 And Recommend Final Dividend If Any.May 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 29, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 28, 2025
Intimation Of Formation Of A Wholly Owned Subsidiary In Dubai United Arab EmiratesApr 28, 2025
Launch Of Four New ProductsApr 24, 2025
Intimation Of Name Change Of Subsidiary CompanyApr 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 31, 2025
Change In Status Of Dr. Morepen Limited - From Wholly Owned Subsidiary To Subsidiary Of The CompanyMar 31, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMar 29, 2025
Closure of Trading WindowMar 27, 2025
Intimation Of Incorporation Of A Step Down Subsidiary CompanyMar 20, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMar 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 17, 2025
Intimation Of Formation Of A Step Down Subsidiary CompanyFeb 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 12, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 10, 2025
Shareholder Meeting / Postal Ballot-Outcome of EGMFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 06, 2025
Integrated Filing (Financial)Feb 06, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 06, 2025
Statement Of Deviation & Variation - Proceeds Of QIP IssueFeb 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 06, 2025

Technical Indicators

RSI(14)
Neutral
59.03
ATR(14)
Volatile
2.29
STOCH(9,6)
Neutral
60.17
STOCH RSI(14)
Neutral
79.36
MACD(12,26)
Bullish
0.06
ADX(14)
Weak Trend
13.80
UO(9)
Bearish
43.10
ROC(12)
Uptrend And Accelerating
4.89
WillR(14)
Overbought
-14.91

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan BSE Healthcare Index Fund Direct-Growth
0.18%
10
0.01%
0.04%